Welcome to our dedicated page for Ionis Pharmaceuticals SEC filings (Ticker: IONS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ionis Pharmaceuticals, Inc. filings document an operating biotechnology company focused on RNA-targeted medicines, marketed products, partnered programs, and clinical-stage pipeline assets. Form 8-K reports cover GAAP and non-GAAP financial results, product-sales updates, Regulation FD disclosures, clinical data releases, and regulatory communications involving programs such as zilganersen in Alexander disease and bepirovirsen in chronic hepatitis B.
Proxy materials describe annual meeting procedures, director matters, board governance, and stockholder voting items. Other filings record capital-structure events and material agreements, including the completed private offering of convertible senior notes due 2030, along with exhibit filings and related corporate disclosures.
Ionis Pharmaceuticals reported new clinical data for its experimental drug olezarsen in people with severe hypertriglyceridemia, a condition marked by very high blood fats. The company shared what it described as positive results from an ongoing extension of its CORE and CORE2 studies at a major lipid conference in Chicago.
The update focused on liver fat measurements using MRI technology in 53 patients who completed 12 months of treatment in the CORE open-label extension, all on an 80 mg dose of olezarsen. These patients represented about 25% of those enrolled in a dedicated liver fat substudy, which tracks hepatic fat fraction over time.
Ionis Pharmaceuticals director Peter N. Reikes received a grant of non-qualified stock options covering 10,753 shares of common stock. The options have an exercise price of $75.13 per share and were awarded under the company’s Amended & Restated 2002 Non-Employee Directors' Stock Option Plan.
The grant vests in three equal annual installments, with the first tranche vesting and becoming exercisable on June 4, 2027, and the options becoming fully vested and exercisable on June 4, 2029. The options expire on June 4, 2036. This is a compensation-related award rather than an open-market purchase or sale.
Ionis Pharmaceuticals director Ludwig Hantson received a grant of non-qualified stock options covering 10,753 shares of common stock at an exercise price of $75.13 per share. The options were granted at no cost as director compensation, vesting in three equal annual installments starting on June 4, 2027, and will be fully vested by June 4, 2029. The options expire on June 4, 2036, and were not exercisable as of the grant date.
IONIS PHARMACEUTICALS INC filed an initial Form 3 for Peter N. Reikes, who is identified as a director of the company and not a ten percent owner or officer. The filing reports no transactions or holdings data, serving as a baseline statement of beneficial ownership.
IONIS PHARMACEUTICALS INC director Ludwig Hantson filed an initial Form 3, which is a mandatory statement of beneficial ownership for insiders. This filing establishes his status as a director-level insider of the company but does not report any stock transactions or specific holdings.
Ionis Pharmaceuticals reported governance updates and voting results from its 2026 annual stockholder meeting. The board appointed biopharmaceutical executive Ludwig Hantson, Ph.D., effective June 4, 2026. He brings more than 30 years of leadership experience at companies including Alexion, Baxter Bioscience/Baxalta, Novartis and Johnson & Johnson.
Stockholders elected directors Spencer R. Berthelsen and Joan E. Herman and approved, on an advisory basis, the compensation of named executive officers. They approved increasing the 2011 Equity Incentive Plan share authorization by 9,500,000 shares to 52,000,000 shares and expanding the Employee Stock Purchase Plan by 750,000 shares while removing its termination date. Stockholders also ratified Ernst & Young LLP as independent auditors for the 2026 fiscal year.
IONIS PHARMACEUTICALS INC director Spencer R. Berthelsen reported an option exercise paired with a share sale. On June 1, 2026, he exercised a non-qualified stock option for 8,000 shares of common stock at $24.42 per share and then sold 8,000 shares in an open-market transaction at $75.67 per share. After these transactions, he directly held 156,013 shares of common stock. The filing also shows 70 shares held indirectly by his daughter, for which he disclaims beneficial ownership. The sale was executed under a Rule 10b5-1 Trading Plan adopted on September 12, 2025, indicating it was pre-arranged.
Ionis Pharmaceuticals reported that its partner GSK released positive pivotal Phase 3 data for bepirovirsen, an investigational antisense oligonucleotide for chronic hepatitis B. Across the B-Well 1 and B-Well 2 trials, six months of treatment produced a 19% functional cure rate (233 of 1,220) in adults with baseline hepatitis B surface antigen ≤3000 IU/mL, compared with 0% in the placebo group, meeting the primary endpoints.
In patients with baseline HBsAg ≤1000 IU/mL, a key secondary endpoint showed a 26% functional cure rate (200 of 768 vs. 0 of 393 on placebo). An exploratory analysis found 49% of bepirovirsen recipients reached qHBsAg ≤100 IU/mL one year after treatment, and 23% overall (31% in the ≤1000 IU/mL subgroup) achieved sustained DNA <LLOQ at week 72. Bepirovirsen is under FDA priority review with Breakthrough and Fast Track designations and is also under review in Europe, Japan and China. Ionis is eligible for additional regulatory and sales milestone payments and tiered royalties of 10–12% on net sales.
Ionis Pharmaceuticals Chief Executive Officer Brett P. Monia reported an exercise-and-sell transaction in company stock. On May 13–14, Monia exercised options to acquire a total of 4,536 shares of common stock at an exercise price of $32.60 per share, then sold the same number of shares in open-market trades at weighted average prices of about $78.01 and $78.68. The sales were carried out under a pre-arranged Rule 10b5-1 Trading Plan adopted on December 8, 2025. Following these transactions, Monia directly holds 242,662 shares of Ionis common stock, indicating that only a small portion of the position was sold.